New ultrasound technique aims to spot cancer without radiation
NCT ID NCT04136912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new 3D ultrasound technique called acoustic angiography to improve imaging of breast and thyroid tumors. Researchers planned to enroll 45 people, including healthy volunteers and patients scheduled for biopsy. The study was stopped early due to funding problems, so only limited data were collected.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- perflutren (Definity)
- What this could lead to
- If successful, this imaging method could help doctors see tiny blood vessels in tumors more clearly, potentially improving cancer detection without radiation.
- What could go wrong
- The study was terminated early due to lack of funding, so results are very limited. It was a small, early-phase trial, and the technique may not prove better than standard ultrasound.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
27 people
The number who actually took part.
- Started
-
May 2022
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Healthy Volunteers Inclusion Criteria * Able to provide informed consent * Negative urine pregnancy test in women of child-bearing potential Exclusion Criteria * Institutionalized subject (prisoner or nursing home patient) * Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) * Known hypersensitivity to perflutren lipid (Definity®) * Active cardiac disease including any of the following: * Severe congestive heart failure * Unstable angina. * Severe arrhythmia * Myocardial infarction within 14 days prior to the date of proposed Definity® administration. * Pulmonary hypertension * Cardiac shunts Breast Imaging Patients Inclusion Criteria * Women * Patient had a diagnostic breast ultrasound study performed at UNC * Scheduled for a core needle or surgical breast biopsy of at least one breast lesion that is 2 cm or less in size and 3 cm in depth from the skin surface * Able to provide informed consent * Negative urine pregnancy test in women of child-bearing potential * BIRADS score of 4 or 5. Exclusion Criteria * Male * Institutionalized subject (prisoner or nursing home patient) * Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) * Sonographically visible breast lesion larger than 2cm or greater than 3cm in depth from the skin surface * Known hypersensitivity to perflutren lipid (Definity®) * Active cardiac disease including any of the following: * Severe congestive heart failure * Unstable angina. * Severe arrhythmia * Myocardial infarction within 14 days prior to the date of proposed Definity® administration. * Pulmonary hypertension * Cardiac shunts Thyroid Imaging Patients Inclusion Criteria * Patient had a diagnostic thyroid ultrasound study performed at UNC * TIRADS risk score of 4c or 5 * Scheduled for a core needle or surgical thyroid biopsy, fine needle aspiration, or thyroidectomy of at least one sonographically visible thyroid lesion that is 3 cm in depth from the skin surface * Able to provide informed consent * Negative urine pregnancy test in women of child-bearing potential Exclusion Criteria * Institutionalized subject (prisoner or nursing home patient) * Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) * Known hypersensitivity to perflutren lipid (Definity®) * Active cardiac disease including any of the following: * Severe congestive heart failure * Unstable angina. * Severe arrhythmia * Myocardial infarction within 14 days prior to the date of proposed Definity® administration. * Pulmonary hypertension * Cardiac shunts
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Univeristy of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?